Ikonen E, Peltonen L
Department of Human Molecular Genetics, National Public Health Institute, Helsinki, Finland.
Hum Mutat. 1992;1(5):361-5. doi: 10.1002/humu.1380010503.
This article provides a review of the mutations reported so far in the lysosomal storage disease aspartylglucosaminuria (AGU). The clinical symptoms, biochemical findings, and diagnostic possibilities of the disease are introduced. The prevalence and biological consequences of the found mutations are then described, as well as the availability of a new rapid DNA test suitable for carrier screening. This test will be especially applicable in the genetically isolated Finnish population, where the carrier frequency of AGU was found to be as high as 1:36. Finally, future prospects dealing with the foreseeable therapeutic interventions of the disease are discussed.
本文综述了迄今为止在溶酶体贮积病天冬氨酰葡糖胺尿症(AGU)中报道的突变情况。介绍了该疾病的临床症状、生化检查结果及诊断方法。随后描述了所发现突变的发生率和生物学后果,以及一种适用于携带者筛查的新型快速DNA检测方法。这种检测方法在遗传上相对隔离的芬兰人群中尤为适用,在该人群中AGU携带者频率高达1:36。最后,讨论了该疾病可预见的治疗干预措施的未来前景。